Skip to content
Fondation Leenaards

Leenaards Foundation 2023 Science Prizes

Share this article

Leenaards Foundation announces three winners of the 2023 Science Prizes. CHF 1.5 million are awarded to support biomedical research in the Swiss Health Valley


The Leenaards Foundation will hand out its annual Science Prize, together with over CHF 1.5 million in award money, to three research groups in the Lake Geneva region at a ceremony on 23 March 2023. The research groups are headed by Dr. Sylvain Meylan (CHUV), who is addressing the problem of antibiotic resistance with a new antibiotic-treatment strategy based on sugar; Dr. Indrit Bègue (UNIGE and HUG), who is investigating cerebellar stimulation as a method for alleviating certain symptoms of schizophrenia, such as apathy; and Prof. Julien Vaucher (CHUV), who is working to better understand the causal link between genetic markers and cardiovascular disease.

The awards ceremony will be open to the public. It will also include a talk by Prof. Alexandre Pouget from the University of Geneva, who will explore the various societal challenges arising from the use of artificial intelligence.

Using sugar to treat post-operative urology infections

The research team is led by Dr Sylvain Meylan (CHUV, right), Prof. John McKinney (EPFL, center), Prof. Beat Roth (CHUV, left) © Alban Kakulya

“We’re exploring the possibility of using cerebellar stimulation to expand the range of treatment options for the negative symptoms of schizophrenia, such as apathy,” says Dr. Meylan, the chief resident in infectious diseases at Lausanne University Hospital (CHUV). This work is important because up to 40% of patients who are given a urinary probe or catheter go on to develop a severe urinary tract infection.

Dr. Meylan is leading a translational research team including Prof. Beat Roth, the chief physician at the CHUV’s urology department, and Prof. John McKinney, the head of EPFL’s Laboratory of Microbiology and Microtechnology. They’re studying the best way to lure bacteria by administering mannitol in order to “wake them up” and make them more susceptible to antibiotics. “We hope that our new strategy for fighting bacterial infection could one day be used in fields other than urology as well and help mitigate the problem of antibiotic resistance, which is becoming an increasingly worrying public-health issue,” says Dr. Meylan.



Cerebellar stimulation can address the negative symptoms of schizophrenia

The research team is led by Dre Indrit Bègue (HUG-UNIGE, right), Prof. Camilla Bellone (UNIGE, left), Dr Jonas Richiardi (CHUV-UNIL, up) © Alban Kakulya

Around 85,000 people in Switzerland suffer from schizophrenia. This psychiatric disorder usually manifests as an altered perception of reality and leads to symptoms such as withdrawal and apathy.

“Our research hypothesis is that we can reduce the intensity of these negative symptoms by stimulating the cerebellum, which is located at the back of the brain,” says Dr. Bègue, from the University of Geneva’s Department of Psychiatry and Geneva University Hospital. She’s running this project alongside Prof. Camilla Bellone from the University of Geneva’s Department of Basic Neurosciences and Dr. Jonas Richiardi from the CHUV’s Department of Radiology. The cerebellum contains over 50% of the brain’s neurons and is connected to regions deep within the brain that are associated with our reward system. “The kind of stimulation we’re studying could reactivate the reward systems of patients suffering from schizophrenia, thus helping them recover a more normal level of social interaction,” says Dr. Bègue.



Lausanne residents are helping doctors better understand cardiovascular disease

The research team is led by Prof. Julien Vaucher (CHUV, right), Prof. Freddy Radtke (ISREC-EPFL, center), Prof. Jacqueline Schoumans (CHUV, left). © Alban Kakulya





“Our goal is to better understand the mechanisms that cause someone with no apparent risk factor – like smoking, drinking or high blood pressure – to nevertheless develop cardiovascular disease,” says Prof. Vaucher, who is conducting the research along with Prof. Jacqueline Schoumans, the head of the CHUV’s Cancer Genomics Laboratory, and Prof. Freddy Radtke from EPFL’s School of Life Sciences.

“Some people carrying a specific genetic marker seem more likely to develop an inflammation that could lead to cardiovascular disease,” says Prof. Vaucher. He’s the principal investigator in the CHUV’s CoLaus I PsyCoLaus cohort study, which has been collecting data on a representative sample of Lausanne residents (more than 6,700 volunteers) over the past 20 years. Data from a selection of this cohort are part of what’s being used in this research project to investigate the causal link between genetic markers and cardiovascular disease.


Source: Press Release